Beam Therapeutics' BEAM-302 Shows Durable AATD Correction in Phase 1/2 Trial
Event summary
- Beam Therapeutics presented additional Phase 1/2 trial data for BEAM-302 at the ATS 2026 International Conference on May 18, 2026.
- Topline data from 29 patients showed durable correction of the PiZ mutation in Alpha-1 Antitrypsin Deficiency (AATD).
- BEAM-302 demonstrated reduction in human neutrophil elastase activity, indicating restored AAT function.
- Beam plans to enroll 50 additional patients in the trial's pivotal cohort, initiating in H2 2026.
The big picture
Beam Therapeutics' BEAM-302 represents a potential paradigm shift in treating AATD by addressing the root cause of the disease through base editing. The durable correction of the PiZ mutation positions BEAM-302 as a potential curative therapy, contrasting with current protein replacement treatments. The company's strategic focus on expanding patient enrollment and pursuing accelerated approval underscores its ambition to lead in the gene editing space.
What we're watching
- Regulatory Pathway
- Whether the FDA's accelerated approval pathway will expedite BEAM-302's market entry.
- Clinical Execution
- The pace at which Beam enrolls the additional 50 patients in the pivotal cohort.
- Competitive Positioning
- How durable correction of AATD will differentiate BEAM-302 from existing protein replacement therapies.
Related topics